RxDoctor Payments Data

Kebai Bills

Medical · Pocatello, IDNPI 1750342952

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 25.7% of the total.

$2,497in general payments, 2019–2025

Across 134 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$642
  • AbbVie$551
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$258
  • Axsome Therapeutics, Inc.$203
  • Alkermes, Inc.$198
  • Otsuka America Pharmaceutical, Inc.$173
  • plus $473 from 9 others

What the payments were for

  • Food & beverage$2,38696%
  • Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,497 in reported general payments places this provider in the 85th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho

Medicare billing

Part B allowed, 2024
$12,202
Medicare patients
38
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl29$39,769
AuvelityDextromethorphan Hbr/Bupropion19$27,881
TrintellixVortioxetine Hydrobromide32$24,687
Clozapine104$12,019
Paliperidone ErPaliperidone39$8,925
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$4,702
Varenicline Tartrate17$3,761
Trazodone Hcl70$3,122
Aripiprazole32$3,013
Duloxetine Hcl110$2,906
Divalproex Sodium ErDivalproex Sodium54$2,311
Lurasidone Hcl15$1,919
Methylphenidate Er (La)Methylphenidate Hcl12$1,844
Eszopiclone17$1,714
Olanzapine45$1,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$551$39,76929 claims
Axsome Therapeutics, Inc.Auvelity$203$27,88119 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$69$24,68732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 265 medical providers in Idaho.

Other medical in Pocatello

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →